Arrowstreet Capital, Limited Partnership Abb Vie Inc. Transaction History

Arrowstreet Capital, Limited Partnership

$114 Billion
Q2 2024

A detailed history of Arrowstreet Capital, Limited Partnership transactions in Abb Vie Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 183,074 shares of ABBV stock, worth $35.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

183,074

Previous 85,680 113.67%

Holding current value

$35.1 Million

Previous $15.6 Million 101.26%

% of portfolio

0.03%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $15.1 Million - $17.6 Million	97,394 Added 113.67%	183,074 $31.4 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $42.1 Million - $48 Million	-263,428 Reduced 75.46%	85,680 $15.6 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $38.2 Million - $43 Million	277,358 Added 386.56%	349,108 $54.1 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $616,117 - $713,245	4,612 Added 6.87%	71,750 $10.7 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $6.78 Million - $8.44 Million	51,202 Added 321.3%	67,138 $9.05 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $2.3 Million - $2.65 Million	15,936 New	15,936 $2.54 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $142 Million - $162 Million	-1,055,102 Reduced 24.7%	3,215,907 $432 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $52.4 Million - $66.7 Million	-381,113 Reduced 8.19%	4,271,009 $654 Million
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $497 Million - $617 Million	3,768,579 Added 426.53%	4,652,122 $754 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $111 Million - $140 Million	-1,029,449 Reduced 53.81%	883,543 $120 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $192 Million - $218 Million	1,804,393 Added 1661.52%	1,912,992 $206 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $2.26 Million - $2.52 Million	-21,501 Reduced 16.53%	108,599 $12.2 Million
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $13.3 Million - $14.7 Million	130,100 New	130,100 $14.1 Million
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $20.4 Million - $27.5 Million	-253,000 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $18.9 Million - $22.2 Million	220,000 Added 666.67%	253,000 $22.2 Million
Q2 2020 Aug 12, 2020	SELL	$73.37 - $98.18 $420 Million - $562 Million	-5,722,097 Reduced 99.43%	33,000 $3.24 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $40.4 Million - $61.3 Million	626,639 Added 12.22%	5,755,097 $438 Million
Q4 2019 Feb 13, 2020	SELL	$72.13 - $90.25 $168 Million - $211 Million	-2,335,648 Reduced 31.29%	5,128,458 $454 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $4.1 Million - $4.93 Million	65,172 Added 0.88%	7,464,106 $565 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $31.7 Million - $40.6 Million	483,145 Added 6.99%	7,398,934 $538 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $17.6 Million - $20.7 Million	-228,540 Reduced 3.2%	6,915,789 $557 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $149 Million - $184 Million	-1,918,859 Reduced 21.17%	7,144,329 $659 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $259 Million - $288 Million	-2,917,106 Reduced 24.35%	9,063,188 $857 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $338 Million - $400 Million	3,763,730 Added 45.81%	11,980,294 $1.11 Billion
Q1 2018 May 14, 2018	BUY	$92.01 - $123.21 $564 Million - $756 Million	6,133,793 Added 294.5%	8,216,564 $778 Million
Q4 2017 Feb 09, 2018	SELL	$89.56 - $98.21 $70.4 Million - $77.2 Million	-786,282 Reduced 27.41%	2,082,771 $201 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $200 Million - $256 Million	2,869,053	2,869,053 $255 Million

Others Institutions Holding ABBV

# of Institutions

3,694

Shares Held

1.27B

Call Options Held

13M

Put Options Held

9.79M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $339B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account

Arrowstreet Capital, Limited Partnership Abb Vie Inc. Transaction History